Nutritional Growth Solutions appoints new CFO
Health & Biotech
Health & Biotech
Nutritional Growth Solutions has appointed a new CFO as it moves to strengthen its position in the global market for children’s nutrition.
Paediatric nutritional products provider Nutritional Growth Solutions (ASX:NGS) has appointed biotech and international pharmaceuticals industries accounting expert Yossi Nizhar as chief financial officer.
Nizhar has more than 20 years accounting experience in the biotech and international pharmaceutical industries.
As a certified public accountant, he served for ~10 years as CFO Israel for global pharmaceutical heavyweight AstraZeneca.
More recently, Nizhar was CFO for Kadimastem (TASE:KDST), a global innovator in cell therapy that develops regenerative therapies for incurable diseases.
He holds an MBA – Business Administration, specialising in Finance from Bar-Ilan University and a BA – Economics and Accounting from Tel Aviv University.
NGS CEO and managing director Liron Fendell has welcomed the appointment of Nizhar.
“Yossi is an outstanding finance professional with extensive experience with listed health-based companies,” Fendell said.
“We look forward to benefiting from his skills as we continue to grow the Healthy Heights brand into a global household name in child nutrition.”
Fendell said she would like to thank outgoing CFO Tzil Peker for his contribution to NGS over the past two years as the company has rapidly grown.
“He has provided valuable support to the business as we scaled our operations and assisted us in the initial phase of our journey,” she said.
“We wish him all the best for his future endeavours.”
She said Nizhar will take over the role from July 1, with Peker CFO until June 30 to ensure an orderly transition.
The company appointed former Blackmores managing director Peter Osborne as strategic advisor for China and Southeast Asia.
NGS also appointed Mark Sargent as advisor for the Australian market. Sargent has more than 20 years’ experience in consumer health, including 18 years at global pharmaceuticals giant Bayer (ETR: BAYN).
This article was developed in collaboration with Nutritional Growth Solutions, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.